05/20/2002 By Harvey McConnell
Chemoembolisation as treatment for patients with liver cancer that cannot be treated surgically or by transplantation could increase survival by two years.
The procedure blocks blood supply to the tumour through use of a gelatin sponge with doxorubicin chemotherapy to inhibit cancer growth. Researchers with the Barcelona Clinic Liver Cancer (BCLC) Group in Spain stopped a randomised, controlled trial in 112 patients after four years when the ninth sequential inspection showed that chemoembolisation had survival benefits compared with conservative treatment. Dr. Jordi Bruix of the Barcelona Hospital Clinic Digestive Disease Institute says: “While we wait for confirmatory studies and from now on, chemoembolisation should become the standard approach for a selected group of candidates.” He includes patients with unresectable intermediate hepatocellular carcinoma and preserved liver function in this group of patients.
The BCLC study also included an embolisation treatment group, with embolisation defined as regularly repeated arterial embolisation through use of a gelatin sponge. Of 35 patients assigned conservative treatment, 25 had died at four years. This compared to 21 deaths among 40 patients assigned to chemoembolisation and 25 deaths among 37 patients assigned to embolisation.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!